Rapid Dose extends precommercialization nicotine deal

Executive Summary

• Rapid Dose Therapeutics extended its exclusive precommercialization and development agreement with its international nicotine partner, retroactively to June 19, 2025, for seven months, with potential value up to $1.8 million.
• The company submitted an application to Health Canada for its NicStrip nicotine products in four dosage formats (1mg, 2mg, 3mg, and 4mg), marking a key step toward Canadian market readiness.
• The release highlights ongoing clinical evaluations, new patent filings, and positive consumer feedback for NicStrip, a fast-dissolving oral thin film designed as a smoke-free nicotine alternative.

Key Details

• Partnership Extension: The exclusive precommercialization and development agreement with the international nicotine partner was extended retroactively to June 19, 2025, for a further seven months from the date of execution.
• Financial Terms: The extension represents up to approximately $1.8 million over the period, subject to termination provisions.
• Regulatory Submission: On August 4, 2025, Rapid Dose submitted an application to Health Canada for NicStrip nicotine products in one-milligram, two-milligram, three-milligram, and four-milligram formats.
• Clinical Trials: A pharmacokinetic study launched in June 2025 under good clinical practice is currently in progress to benchmark NicStrip nicotine absorption against combustible cigarettes to inform regulatory positioning and product claims.
• Intellectual Property: In May 2025, Rapid Dose and its collaborative development partner filed two international PCT patent applications covering dissolvable and non-dissolvable nicotine oral strip formats.
• Product Specifications: NicStrip is a fast-dissolving oral thin film delivering nicotine through oral mucosa. It offers customizable nicotine strengths (1 to 12 milligrams), flavors, and dissolution profiles.
• Market Data:
  • Canadian nicotine pouches market valued at $112.2 million (U.S.) in 2024, with 4.7% annual growth projected through 2030.
  • Global nicotine pouches market valued at ~$5.39 billion (U.S.) in 2024, projected to reach ~$25.40 billion by 2030 (CAGR ~29.6%).
  • Modern oral nicotine products category estimated at $6.8 billion (U.S.) in 2024, forecast to reach $75.7 billion by 2034 (CAGR ~27.7%).
  • North American nicotine pouch market valued at $2.42 billion (U.S.) in 2022, projected to reach $4.06 billion by 2030 (CAGR ~6.7%).

Notable Quotes

• "This extension marks an important milestone in advancing NicStrip toward potential commercialization discussions with our international nicotine partner. We appreciate the collaborative spirit and look forward to advancing these evaluations together," said Mark Upsdell, chief executive officer of Rapid Dose Therapeutics.
• "This continued collaboration allows both parties to further their evaluations of NicStrip as part of the broader shift toward smoke-free alternatives. The financial commitment embedded in this extension underscores the shared seriousness in exploring a pathway to market in a rapidly evolving nicotine alternatives sector," said Jason Lewis, senior vice-president of Rapid Dose Therapeutics.